Understanding these issues will ultimately lead to the development of more potent dendritic cell-based vaccines for cancer and other diseases, as well as novel strategies to target endogenous DCs in vivo to generate optimal CD8+ T-cell priming against defined antigens. Here, CD8A is linked to cancer.